▲ +67.90% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for CV Sciences in the last 3 months. The average price target is $0.68, with a high forecast of $0.95 and a low forecast of $0.50. The average price target represents a 67.90% upside from the last price of $0.40.
The current consensus among 4 contributing investment analysts is to hold stock in CV Sciences. This rating has held steady since April 2020, when it changed from a Buy consensus rating.
CV Sciences, Inc. operates as a life science company in the United States. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD name in various market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchandise retailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.